Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

  • End date
    Jun 18, 2023
  • participants needed
  • sponsor
    Fudan University
Updated on 18 October 2021
radical cystectomy
neutrophil count
invasive bladder cancer
bladder tumor
bladder instillation


This study will evaluate the safety of bladder instillation with Camrelizumab and compare to the efficacy of intravesical therapy with intravenous therapy using Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.

Condition Bladder Carcinoma, immunotherapies, Urothelial Cancer, Bladder Cancer, Bladder Disorders, bladder tumor, Immunotherapy, bladder cancer, urinary tract neoplasm, Urologic Cancer, bladder disorder
Treatment Camrelizumab
Clinical Study IdentifierNCT04706598
SponsorFudan University
Last Modified on18 October 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years
Histologically-confirmed diagnosis of high risk non-muscle-invasive urothelial cell carcinoma of the bladder (mixed histology tumors allowed if urothelial carcinoma histology is >50%)
Fully resected disease at study entry (residual CIS acceptable)
BCG-unresponsive high risk non-muscle-invasive bladder cancer after treatment with adequate BCG therapy(at least five times a week during the induction phase and at least two times a week during the maintenance phase)
Ineligible for radical cystectomy or refusal of radical cystectomy
Consent to tissue specimen retrieval and testing
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Adequate normal organ and marrow function as defined below
Haemoglobin (HB) 90 g/L
Absolute neutrophil count (ANC) 1500/uL(no granulocyte colony-stimulating factor support for 2 weeks before day 1 of cycle 1)
Lymphocyte count0.50010^9/L
Platelet count 10010^9/L(No blood transfusions within 2 weeks before day 1 of cycle 1)
4.010^9/LWhite Blood Cell Count (WBC)1510^9/L
AST (SGOT)/ALT (SGPT)/Alkaline phosphatase 2.5 x institutional upper limit of normal(ULN) unless patients with known Gilbert's disease, in which its case serum bilirubin level must be 3x ULN
INR/aPTT1.5ULN(Which only applies to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be given a stable dose)
Serum creatinine (Cr) 1.5 times the upper institutional limit of normal (ULN) or Serum creatinine Cl>60 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)
Women of childbearing potential who have a negative serum pregnancy test within 72 hours prior to the first dose should consent to and must use effective contraception during and for 6 months after the end of the study
Men should consent to patients who must use contraception during the study and for 6 months after the end of the study period
The subject is personally willing and able to provide written informed consent to be able to comply with the protocol

Exclusion Criteria

Muscle-invasive, locally advanced nonresectable, or metastatic urothelial carcinoma
Concurrent extra-vesical (i.e., urethra, ureter, or renal pelvis)urothelial cell carcinoma
Have participated in a clinical trial of an investigational drug or device within 4 weeks prior to receiving the first treatment in this project
Received chemotherapy, targeted small molecule therapy, immunotherapy or radiation therapy following a recent cystoscopy or transurethral resection of a bladder tumour
History of other malignancies within the last 5 years
Active autoimmune disease that has required systemic treatment in the past 2 years
History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonia, histoplasmosis (i.e. occlusive bronchiolitis, cryptogenic histoplasmosis), or evidence of active pneumonia on chest CT scan (history of fibrosis in radiation pneumonia), patients with active tuberculosis
Active infection requiring systemic therapy,therapeutic oral or intravenous (IV) antibiotics within 14 days prior to enrolment (patients receiving prophylactic antibiotics (e.g. for the prevention of urinary tract infections or chronic obstructive pulmonary disease) can be enrolled)
Patients who are pregnant or breastfeeding, or expecting to conceive
Previous treatment with anti-PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA-4 monoclonal antibody, or other drugs that act on T-cell co-stimulation or any other antibody of the checkpoint pathway
Patients with known positive test for human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS)
Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (Hepatitis B reference: HBsAg positive and HBV DNA 500 IU/ml; Hepatitis C reference: HCV antibody positive and HCV viral copy number > upper limit of normal value)
Received a live virus vaccine within 30 days of planned start of study treatment
Has had an allogeneic tissue/solid organ transplant
Long-term oral steroids, more than 10 mg/day of methandrostenolone or similar, must be stopped for 28 days before entry into the group
Evidence of apparently uncontrolled concomitant disease that may affect compliance with the protocol or interpretation of the results, including significant liver disease (e.g. cirrhosis, uncontrolled major seizures or superior vena cava syndrome)
Significant cardiovascular disease, such as New York Heart Association heart attack (class II or higher), myocardial infarction, unstable arrhythmia or unstable angina within 3 months prior to study entry
Patients who have had major surgery within 4 weeks prior to study entry, or who are expected to require major surgery during the course of the study, except diagnostic procedures such as TURBT or biopsy
History of autoimmune diseases, including but not limited to severe muscle weakness, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, angio-thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, dry syndrome, Guillain-Barr syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
History of severe allergy, sensitisation or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins
Patients who, in the opinion of the investigator, are otherwise unable to participate in this trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note